With three deals over as many weeks, France’s Ipsen SA has rapidly beefed up its access to external innovation in its targeted therapeutic areas of oncology/hematology, rare diseases and neurology, with the latest agreement being an exclusive option on two discovery programs at Chicago-based Exicure, Inc., in two rare neurodegenerative diseases, Huntington’s disease and Angelman syndrome.
Ipsen Targets External Innovation With Exicure Option In Rare Neurodegenerative Disorders
Pacts In Huntington's Disease, Angelman Syndrome
France’s Ipsen has taken an exclusive option on two neurodegenerative disease programs at US biotech Exicure, whose oligonucleotide nanoparticles are taken up by many tissues, including the brain.

More from Rare Diseases
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.
More from Scrip
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.